![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, January 22, 2017 8:22:29 PM
http://www.owcpharma.com/wp-content/uploads/2017/01/OWC-PPT-1-2017-FINAL.pdf
• Two products ready to market:
• Sublingual Soluble tablet: replacement of smoking, pain
treatment. more than 10 million potential patients in the approved
MMJ states.
• Topical crème: Treatment for different skin diseases starting with
tested psoriasis. ~8 Million Psoriasis patients US & Canada (2.5% of
population), 3 years potential is 2-4 millions monthly income
(following current market prices)
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM